Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed)
The summary for the Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with T2D and related forms of islet dysfunction, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through use and expansion of the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.
Federal Grant Title: | Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DK-18-016 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.847 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | February 26th, 2019 |
Original Application Deadline: | February 26th, 2019 |
Posted Date: | October 10th, 2018 |
Creation Date: | October 10th, 2018 |
Archive Date: | April 3rd, 2019 |
Total Program Funding: | |
Maximum Federal Grant Award: | $2,000,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | October 11th, 2018 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-016.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...
- • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...
- • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...
- • Diabetes Research Centers (P30 Clinical Trial Optional)
- • Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
- • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
- • Molecular Therapy Core Centers
- • Pilot and Feasibility Program in Human Islet Biology
- More Grants from the National Institutes of Health
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...